Carbylan Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.carbylan.com
Clinical Trials
5
Active:0
Completed:4
Trial Phases
4 Phases
Phase 2:1
Phase 3:1
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (25.0%)Phase 2
1 (25.0%)Phase 3
1 (25.0%)Phase 4
1 (25.0%)Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis
Phase 3
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT02022930
Hydros Joint Therapy and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis (OA)
Phase 2
Completed
- Conditions
- Osteoarthritis of the Knee
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 98
- Registration Number
- NCT01134406
- Locations
- 🇨🇦
London Health Sciences Centre Research, London, Ontario, Canada
ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee
Not Applicable
Terminated
- Conditions
- Osteoarthritis
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00665574
- Locations
- 🇱🇻
Daugavpils Pilsetas Centrala Slimnica, Daugavpils, Latvia
🇱🇻State Hospital of Traumatology and Orthopaedics, Riga, Latvia
Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel
Phase 4
Completed
- Conditions
- Ethmoid SinusitisRhinosinusitis
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- Carbylan Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00554190
- Locations
- 🇺🇸
Alabama Nasal & Sinus Center, Birmingham, Alabama, United States
🇺🇸University of California, San Francisco, Dept of Otolaryngology, San Francisco, California, United States
🇺🇸Northwestern University Medical Center, Department of Otolaryngology, Chicago, Illinois, United States
News
No news found